The bioavailability and formulation can also differ
Mathapati S, Siller R, et,al
(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement
However, under pathological conditions, Fe2+ accumulates within the cell, engaging in the Haber-Weiss and Fenton reactions, leading to the generation of excessive ROS
It may have stopped working because your skin did
Zhang Y, Li M, Wang Y, Han F, Shen K, Luo L, Li Y, Jia Y, Zhang J, Cai W, Wang K, Zhao M, Wang J, Gao X, Tian C, Guo B, Hu D